Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome - DTU Orbit (20/02/2019)

Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

Purpose: High-grade serous cancer (HGSC) is the most common cancer of the ovary and is characterized by chromosomal instability. Defects in homologous recombination repair (HRR) are associated with genomic instability in HGSC, and are exploited by therapy targeting DNA repair. Defective HRR causes uniparental deletions and loss of heterozygosity (LOH). Our purpose is to profile LOH in HGSC and correlate our findings to clinical outcome, and compare HGSC and high-grade breast cancers.

Experimental Design: We examined LOH and copy number changes using single nucleotide polymorphism array data from three HGSC cohorts and compared results to a cohort of high-grade breast cancers.

Results: LOH-based clustering divided HGSC into two clusters. The major group displayed extensive LOH and was further divided into two subgroups. The second group contained remarkably less LOH. BRCA1 promoter methylation was associated with the major group. LOH clusters were reproducible when validated in two independent HGSC datasets. LOH burden in the major cluster of HGSC was similar to triple-negative, and distinct from other high-grade breast cancers. Our analysis revealed an LOH cluster with lower treatment resistance and a significant correlation between LOH burden and PFS.

Conclusions: Separating HGSC by LOH-based clustering produces remarkably stable subgroups in three different cohorts. Patients in the various LOH clusters differed with respect to chemotherapy resistance, and the extent of LOH correlated with PFS. LOH burden may indicate vulnerability to treatment targeting DNA repair, such as PARP1 inhibitors. Clin Cancer Res; 18(20); 5806–15. ©2012 AACR.

General information
State: Published
Organisations: Center for Biological Sequence Analysis, Department of Systems Biology, Dana-Farber Cancer Institute, Dana-Faber Cancer Institute, University of Melbourne, Haukeland University Hospital, University of Sydney, Brigham and Women's Hospital
Pages: 5806-5815
Publication date: 2012
Peer-reviewed: Yes

Publication information
Journal: Clinical Cancer Research
Volume: 18
Issue number: 20
ISSN (Print): 1078-0432
Ratings:
BFI (2019): BFI-level 2
Web of Science (2019): Indexed yes
BFI (2018): BFI-level 2
Web of Science (2018): Indexed yes
BFI (2017): BFI-level 2
Scopus rating (2017): CiteScore 8.38 SJR 4.929 SNIP 1.904
Web of Science (2017): Impact factor 10.199
Web of Science (2017): Indexed yes
BFI (2016): BFI-level 2
Scopus rating (2016): CiteScore 8.34 SJR 4.846 SNIP 1.982
BFI (2015): BFI-level 2
Scopus rating (2015): CiteScore 8.39 SJR 5.291 SNIP 2.121
Web of Science (2015): Impact factor 8.738
BFI (2014): BFI-level 2
Scopus rating (2014): CiteScore 8.13 SJR 4.947 SNIP 2.086
Web of Science (2014): Impact factor 8.722
Web of Science (2014): Indexed yes
BFI (2013): BFI-level 2
Scopus rating (2013): CiteScore 8.33 SJR 5.093 SNIP 2.083
Web of Science (2013): Impact factor 8.193
ISI indexed (2013): ISI indexed yes